Osteoporosis in men treated with androgen deprivation therapy for prostate cancer

Journal of Urology

Volumn 167, Issue 5, 2002, Pages 1952-1956

  Ross, Robert W ^a   Small, Eric J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Androgens; Bone and bones; Osteoporosis; Prostate; Prostatic neoplasms

Indexed keywords

ANTIANDROGEN; ANTIESTROGEN; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ESTROGEN; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; VITAMIN D;

BONE ATROPHY; BONE DENSITY; CANCER HORMONE THERAPY; EXERCISE; FRACTURE; HUMAN; HYPOGONADISM; INCIDENCE; MALE; MEDICAL LITERATURE; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW;

EID: 0036229537     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)65060-4     Document Type: Review

References (48)

1. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer
2. Alendronate for the treatment of osteoporosis in men
3. Management of male osteoporosis: Report of the UK Consensus Group
4. Osteoporosis in men
5. Osteoporosis in men: Diagnosis, pathophysiology and prevention
6. Metabolic, endocrine and related bone diseases
7. Metabolic bone disease
8. Assessment of fracture risk by bone density measurements
9. Bone density at various sites for prediction of hip fractures
10. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures
11. Severe osteoporosis in men
12. Risk factors for spinal osteoporosis in men
13. Androgens and bone: Basic aspects
14. Castrated men exhibit bone loss: Effect of calcitonin treatment on biochemical indices of bone remodeling
15. Sex hormones and bone mineral density in elderly men
16. Sex steroids and bone mass in older men
17. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens
18. Aromatization of androgens is important for the skeletal maintenance of aged male rats
19. Studies on prostatic cancer I: The effect of castration, estrogen and of androgen injection on serum phosphastases in metastatic carcinoma of the prostate
20. Studies on prostatic cancer II: The effects of castration on advanced carcinoma of the prostate gland
21. Hormonal therapy for metastatic prostate cancer
22. Primary orchiectomy versus estrogen therapy in advanced prostatic cancer: A randomized study - Results after 7 to 10 years of followup
23. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
24. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer
25. An update on prostate cancer research
26. Immediate vs. deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial
27. The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism
28. 6-GnRH)
29. Osteoporosis after orchiectomy for prostate cancer
30. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma
31. Androgen deprivation therapy for prostate cancer results in significant loss of bone density
32. Progressive osteoporosis during androgen deprivation therapy for prostate cancer
33. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma
34. Skeletal fractures associated with androgen-suppression induced osteoporosis - The clinical incidence and risk factors for prostate cancer patients
35. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma
36. A comparison of the prevalence of osteoporosis and vertebral fractures in men with prostate cancer on various androgen deprivation therapies: Preliminary report
37. Flutamide-mediated androgen blockade evokes osteopenia in the female rat
38. Bone mineral density in patients with prostatic cancer treated with orchiectomy and with estrogens
39. Low dose estrogen decreases bone resorption in older men receiving hormonal suppression for prostate cancer
40. The effect of the herbal supplement PC-SPES on bone mineral density in men with prostate cancer
41. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer
42. Progression delay of prostate tumor skeletal metastasis effects by bisphosphonates
43. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices
44. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases
45. The new bisphosphonate Zomets (zoledronic acid) decreases skeletal complications in both lytic and blastic lesions: A comparison to pamidronate
46. Prospective serial measurements of bone mineral density in prostate cancer patients without bone metastases treated with intermittent androgen suppression
47. Dual energy x-ray absorptiometry in detecting bone loss during androgen deprivation in prostate cancer patients